The potentially $2.1 billion collaboration gives Novo access to technologies that are meant to help optimize the delivery of ...

The Danish drugmaker is collaborating with Vivtex, cofounded by billionaire Robert Langer, to quickly iterate oral versions of successors to Ozempic and Wegovy.

Feb 25 (Reuters) - Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion ...

Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as ...

After its next-generation obesity asset CagriSema lost a head-to-head matchup with Eli Lilly’s Zepbound, Novo Nordisk is ...

Novo Nordisk invests €432M ($506M) in Athlone, Ireland to boost oral glucagon-like peptide-1 manufacturing capacity for global markets by 2028.

Vivtex is set to receive research funding, upfront payments, milestone payments up to $2.1bn, and tiered royalties.

Vivtex, cofounded by renowned MIT professor Robert Langer, stands to make as much as $2.1 billion if milestones are met.

Novo Nordisk announced it had signed a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral obesity and diabetes drugs.

Partnership will leverage Vivtex’s proprietary technologies built to identify optimal oral formulations for peptide and ...

The pharma giant struck a licensing deal to gain access to delivery technologies developed by U.S. startup Vivtex., to deepen its pipeline of next-generation obesity drugs.